Detalles de la búsqueda
1.
The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer.
Nature
; 600(7890): 727-730, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34912120
2.
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.
Oncologist
; 2024 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38815152
3.
LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinoma.
Future Oncol
; : 1-13, 2024 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38695479
4.
Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062.
Jpn J Clin Oncol
; 53(3): 221-229, 2023 Mar 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36533429
5.
Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.
Lancet
; 398(10302): 759-771, 2021 08 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-34454674
6.
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Gastric Cancer
; 22(4): 828-837, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-30911859
7.
KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.
Future Oncol
; 15(10): 1057-1066, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30735435
8.
A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.
Cardiovasc Diabetol
; 16(1): 112, 2017 09 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-28893244
9.
Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study.
Lancet
; 385(9983): 2153-61, 2015 May 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-25743173
10.
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib.
J Lipid Res
; 54(2): 467-72, 2013 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-23172660
11.
Safety of anacetrapib in patients with or at high risk for coronary heart disease.
N Engl J Med
; 363(25): 2406-15, 2010 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-21082868
12.
Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Literature Review and Meta-Analysis.
J Gastrointest Cancer
; 54(4): 1031-1045, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37219679
13.
Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study.
Clin Cancer Res
; 28(16): 3489-3498, 2022 08 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35657979
14.
Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10.
Clin Cancer Res
; 27(7): 1923-1931, 2021 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33446564
15.
Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials.
JAMA Oncol
; 7(6): 895-902, 2021 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33792646
16.
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 6(10): 1571-1580, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32880601
17.
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib.
Am Heart J
; 158(4): 513-519.e3, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19781408
18.
Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients with Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
Am J Cardiol
; 119(3): 388-396, 2017 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27956003
19.
A Multiregional, Randomized Evaluation of the Lipid-Modifying Efficacy and Tolerability of Anacetrapib Added to Ongoing Statin Therapy in Patients With Hypercholesterolemia or Low High-Density Lipoprotein Cholesterol.
Am J Cardiol
; 120(4): 569-576, 2017 Aug 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28624096
20.
Inhibition of intestinal cholesterol absorption by ezetimibe in humans.
Circulation
; 106(15): 1943-8, 2002 Oct 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-12370217